Effectiveness and safety of cenobamate after conversion to monotherapy or dual therapy in real‐world clinical practice
This study highlights the real-world effectiveness and safety of cenobamate, either as monotherapy (after conversion from polytherapy) or in dual therapy, in patients with drug-resistant epilepsy. Cenobamate allows for a significant treatment simplification, resulting in fewer treatment-related adverse events without compromising seizure reduction.
Authors
- Yolanda López-Moreno (ORCID: https://orcid.org/0000-0003-2861-5915)
- José Carlos Estévez María
- Guillermina García Martín (ORCID: https://orcid.org/0000-0003-3894-9716)
- Dulce Campos Blanco
- María Isabel Chamorro Muñoz
- A Fernández-Cabrera
- P. Martínez García
- Raquel Calle
- Estuardo Daniel Castro Ruiz
- Sergio Navarro Conti
- Isabel Ros González
- Irene Lorite Fuentes
- Álvaro Sánchez‐Guijo Benavente
- Pedro Jesús Serrano Castro
Institutions
- Hospital Regional Universitario de Málaga (ES)
- Instituto de Investigación Biosanitaria de Granada (ES)
- Complejo Hospitalario de Jaén (ES)
- Hospital Universitario Reina Sofía (ES)
- Hospital Universitario Lucus Augusti (ES)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Hospital Clínico Universitario de Valladolid (ES)
- Instituto de Investigación Biomédica de Málaga (ES)
- Universidad de Málaga (ES)
Publication Details
- Journal
- Epileptic Disorders
- Published
- 2026-03-27
- DOI
- https://doi.org/10.1002/epd2.70222
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00